Table 4.
improvement | progression | P value | ||
---|---|---|---|---|
(n = 49) | (n = 8) | |||
Age, years, median (range) | 53 (19–74) | 65.5 (47–74) | 0.0118 | |
Gender, n (%) | Male | 31 (63) | 5 (63) | > 0.9999 |
Female | 18 (37) | 3 (38) | ||
DM, n (%) | 10 (20) | 3 (38) | 0.3653 | |
BMI, kg/m2, median (range) | 22 (17.0–29.6) | 22.8 (18.8–28.8) | 0.2104 | |
> 25, n (%) | 5 (10) | 3 (38) | 0.0742 | |
Use of MMF as maintenance immunosuppression, n (%) | 30 (61) | 5 (63) | > 0.9999 | |
Time from symptom onset to MP treatment, days, median (range) |
1 (0–5) | 2.5 (1–10) | 0.0430 | |
Baseline eGFR, ml/min/1.73m2, median (range) | 46 (19.2–99.5) | 44.45 (18.3–73.5) | 0.9451 | |
< 30, n (%) | 4 (8) | 2 (25) | 0.1943 | |
Previous SARS-CoV-2 vaccine, doses, median (range) | 4 (2–6) | 4 (0–5) | 0.8933 |